Press Release Archive

08.12.2025

PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery

08.05.2025

Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance

07.25.2025

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union

07.24.2025

Pfizer Completes Licensing Agreement with 3SBio

07.10.2025

XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

06.26.2025

Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors

06.25.2025

Pfizer Declares Third-Quarter 2025 Dividend

06.25.2025

Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts

06.02.2025

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

05.31.2025

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

05.30.2025

Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

05.22.2025

Astellas and Pfizer’s XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer